RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients

被引：3
|
作者：
Singh, Dave
Banner, Kathy
Newman, Kenneth
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
Bronchodilators; COPD; -; management; Anti-inflammatory;
D O I：
10.1183/13993003.congress-2016.PA4052
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4052
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone
    Calzetta, Luigino
    Page, Clive P.
    Spina, Domenico
    Cazzola, Mario
    Rogliani, Paola
    Facciolo, Francesco
    Matera, Maria Gabriella
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 346 (03): : 414 - 423
  • [22] THE DUAL PHOSPHODIESTERASE 3/4 INHIBITOR, RPL554, STIMULATES RARE CLASS III AND IV CFTR MUTANTS
    Turner, M.
    Thomas, D.
    Hanrahan, J. W.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 150 - 150
  • [23] The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants
    Turner, Mark J.
    Luo, Yishan
    Thomas, David Y.
    Hanrahan, John W.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2020, 318 (05) : L908 - L920
  • [24] Bronchodilation and Symptom Improvement with Ensifentrine, A Dual PDE3/4 Inhibitor: Sub-Group Analyses of a Four Week Randomized, Controlled Trial in Patients with COPD
    Rheault, T.
    Rickard, K.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [25] Late Breaking Abstract - A Dose-Ranging Study of the Inhaled Dual PDE3/4 Inhibitor TQC3721 in COPD Patients
    Luo, Zhu
    Yang, Ling
    Yang, Anqi
    Li, Weiguo
    Yu, Ding
    Li, Weimin
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [26] Rpl554, A Dual Phosphodiesterase 3/4 Inhibitor, Relaxes Human Bronchi And Acts Synergistically With Muscarinic Receptor Antagonists
    Matera, M. G.
    Calzetta, L.
    Spina, D.
    Page, C.
    Facciolo, F.
    Cazzola, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [27] The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia
    Turner, Mark J.
    Matthes, Elizabeth
    Billet, Arnaud
    Ferguson, Amy J.
    Thomas, David Y.
    Randell, Scott H.
    Ostrowski, Lawrence E.
    Abbott-Banner, Kathy
    Hanrahan, John W.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2016, 310 (01) : L59 - L70
  • [28] Rpl554, A First-In-Class Dual Phosphodiesterase (pde)3/4 Inhibitor, Is Equi-Effective As A Bronchodilator To Maximal Doses Of Salbutamol In Asthmatics But With Fewer Adverse Events
    Bjermer, L.
    Stewart, J.
    Abbott-Banner, K. H.
    Newman, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [29] ENSIFENTRINE, AN INVESTIGATIONAL, INHALED PDE3/4 INHIBITOR, DECREASED COPD-RELATED HEALTHCARE RESOURCE UTILIZATION OVER 24 WEEKS
    Wan, E.
    Rickard, K.
    Dixon, A.
    Davidson, J.
    Galloway, S.
    Rheault, T.
    VALUE IN HEALTH, 2024, 27 (06) : S49 - S49
  • [30] Ensifentrine Dual phosphodiesterase PDE3/4 inhibitor Treatment of COPD Treatment of cystic fibrosis
    Calzetta, L.
    Matera, M. Gabriella
    Rogliani, P.
    Cazzola, M.
    DRUGS OF THE FUTURE, 2019, 44 (11) : 845 - 854
12345